Importance of Circulating Tumor DNA Analysis at Diagnosis in Early Triple-negative Breast Cancer Patients

Overview

Journal Breast Cancer

Date 2025 Jan 31

PMID 39890753

Authors

Min-Seung Park

Eun Hye Cho

Youngjin Youn

In-Gu Do

Hee-Yeon Woo

Hyosoon Park

Eun Young Kim

Min-Jung Kwon

Affiliations

Soon will be listed here.

Abstract

Background: Circulating tumor DNA (ctDNA) enables non-invasive evaluation and is considered a promising tool for diagnosis, treatment selection, risk stratification, and disease monitoring. However, while the utility of ctDNA has been demonstrated in advanced-stage cancers, its detection in early breast cancer (EBC) remains limited. This study investigated the characteristics of EBC patients associated with higher ctDNA detectability.

Methods: A total of 101 patients with EBC were enrolled. Formalin-fixed paraffin-embedded samples (FFPEs) were obtained from biopsy tissue, and plasma samples were collected before and after neoadjuvant chemotherapy (NAC). Forty-seven breast cancer-related genes were analyzed using next-generation sequencing. The diagnostic performance of ctDNA was evaluated, and logistic regression analyses were conducted to assess the impact of clinical and molecular factors on ctDNA status.

Results: The most frequently identified gene was TP53 (FFPE, 66.7%; ctDNA, 46.4%), followed by PIK3CA (FFPE, 36.2%; ctDNA, 17.4%). The diagnostic performance of the three most common genes showed a sensitivity range of 11.1-58.7%, specificity of 78.3-100%, and diagnostic accuracy of 65.2-78.3%. The triple-negative breast cancer (TNBC) subtype exhibited the strongest association with ctDNA detection (odds ratio [OR] 209.50, p = 0.005) in multivariate analysis. Also, those who exhibited ctDNA clearance after NAC had a higher pathological complete response rate compared to those without clearance (38.5% vs. 11.1%, p = 0.238).

Conclusions: Our study highlights that ctDNA analysis can complement genetic testing from a single tissue biopsy in breast cancer patients. Furthermore, ctDNA analysis may be particularly important in patients with TNBC.

References

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M . Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66:15-23. PMC: 9465273. DOI: 10.1016/j.breast.2022.08.010. View

Ran R, Ma Y, Wang H, Yang J, Yang J . Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review. Front Oncol. 2023; 12:975463. PMC: 9822772. DOI: 10.3389/fonc.2022.975463. View

Andre F, Ciruelos E, Juric D, Loibl S, Campone M, Mayer I . Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2020; 32(2):208-217. DOI: 10.1016/j.annonc.2020.11.011. View

Turner N, Oliveira M, Howell S, Dalenc F, Cortes J, Gomez Moreno H . Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023; 388(22):2058-2070. PMC: 11335038. DOI: 10.1056/NEJMoa2214131. View

Roulot A, Hequet D, Guinebretiere J, Vincent-Salomon A, Lerebours F, Dubot C . Tumoral heterogeneity of breast cancer. Ann Biol Clin (Paris). 2016; 74(6):653-660. DOI: 10.1684/abc.2016.1192. View

Kudelova E, Smolar M, Holubekova V, Hornakova A, Dvorska D, Lucansky V . Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer. Int J Mol Sci. 2022; 23(23). PMC: 9735793. DOI: 10.3390/ijms232314937. View

Ho P, Lim E, Hartman M, Wong F, Li J . Breast cancer risk stratification using genetic and non-genetic risk assessment tools for 246,142 women in the UK Biobank. Genet Med. 2023; 25(10):100917. DOI: 10.1016/j.gim.2023.100917. View

Ng C, Pemberton H, Reis-Filho J . Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther. 2012; 12(8):1021-32. DOI: 10.1586/era.12.85. View

Cheng F, Su L, Qian C . Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016; 7(30):48832-48841. PMC: 5217053. DOI: 10.18632/oncotarget.9453. View

10.

Adashek J, Janku F, Kurzrock R . Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. Cancers (Basel). 2021; 13(14). PMC: 8306582. DOI: 10.3390/cancers13143600. View

11.

Cho S, Lee H, Jeon S, Kim Y, Kong S, Lee J . Cost-Effectiveness Analysis of Three Diagnostic Strategies for the Detection of Mutation in Advanced Non-Small Cell Lung Cancer. Ann Lab Med. 2023; 43(6):605-613. PMC: 10345179. DOI: 10.3343/alm.2023.43.6.605. View

12.

Larribere L, Martens U . Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors. Cancers (Basel). 2021; 13(22). PMC: 8616165. DOI: 10.3390/cancers13225698. View

13.

Mutter J, Alig S, Esfahani M, Lauer E, Mitschke J, Kurtz D . Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas. J Clin Oncol. 2022; 41(9):1684-1694. PMC: 10419411. DOI: 10.1200/JCO.22.00826. View

14.

Sant M, Bernat-Peguera A, Felip E, Margeli M . Role of ctDNA in Breast Cancer. Cancers (Basel). 2022; 14(2). PMC: 8773730. DOI: 10.3390/cancers14020310. View

15.

Huang C, Tsai Y, Liu C, Lien P, Lin Y, Chao T . Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer. Cancers (Basel). 2023; 15(18). PMC: 10526508. DOI: 10.3390/cancers15184475. View

16.

Moreno F, Gayarre J, Lopez-Tarruella S, Del Monte-Millan M, Picornell A, Alvarez E . Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study. JCO Precis Oncol. 2022; 3:1-16. DOI: 10.1200/PO.18.00263. View

17.

Winn J, Hasse Z, Slifker M, Pei J, Arisi-Fernandez S, Talarchek J . Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer. Int J Mol Sci. 2020; 21(4). PMC: 7072950. DOI: 10.3390/ijms21041290. View

18.

Keup C, Benyaa K, Hauch S, Sprenger-Haussels M, Tewes M, Mach P . Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. Cell Mol Life Sci. 2019; 77(3):497-509. PMC: 7010653. DOI: 10.1007/s00018-019-03189-z. View

19.

Griffith O, Spies N, Anurag M, Griffith M, Luo J, Tu D . The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018; 9(1):3476. PMC: 6123466. DOI: 10.1038/s41467-018-05914-x. View

20.

Shibayama T, Low S, Ono M, Kobayashi T, Kobayashi K, Fukada I . Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020; 180(2):331-341. DOI: 10.1007/s10549-019-05512-5. View